Role of fluorodeoxyglucose positron emission tomography in oncological surgery;Die Rolle der FDG-PET in der onkologischen Chirurgie

Chirurg

Volumn 72, Issue 5, 2001, Pages 528-536

  Schurmann G ^a   Franzius, Ch ^b   Twelker, L ^b   Senninger, N ^b   Schober, O ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b NONE

Author keywords

Esophageal cancer; FDG PET; Pancreatic cancer; Positron emission tomography; Recurrent rectal cancer

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; REOPERATION; SCINTISCANNING; TUMOR RECURRENCE;

BLOOD GLUCOSE; ENERGY METABOLISM; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PREDICTIVE VALUE OF TESTS; REOPERATION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035349772     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001040051343     Document Type: Review

References (65)

1. Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, et al (1998) Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathology and CT findings. Radiology 206: 755
2. ACC/AHA (1995) Task force report. Guidelines for clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascuscular procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology. J Am Coll Cardiol 25: 521
3. Bakheet SM, Powe J (1998) Benign causes of 18-FDG uptake on whole-body imaging. Semin Nucl Med 28: 352
4. Bares R, Dohmen BM, Cremerius U, Fass J, et al (1996) Ergebnisse der Positronenemissionstomographie mit Fluor-18-markierter Fluordesoxyglukose bei Differentialdiagnose und Staging des Pankreascarcinoms. Radiologe 36: 435
5. Bender H, Schomburg A, Albers P, Ruhlmann J, Biersack HJ (1997) Possible role of FDG-PET in the evaluation of urologic malignancies. Anticancer Res 17: 1655
6. Bury T, Barreto A, Daenen F, Barthelemy N, et al (1998) Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 25: 1244
7. Bury T, Dowlati A, Paulus P, Corhay JL, et al (1996) Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 6: 410
8. Cai J, Chu JC, Recine D, Sharma M, et al (1999) CT and PET lung image registration and fusion in radiotherapy treatment planning using the chamfer-matching method. Int J Radiat Oncol Biol Phys 43: 883
9. Chin R Jr, Ward R, Keyes JW Jr, Choplin RH, et al (1995) Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Resp Crit Care Med 152: 2090
10. Cook GJR, Fogelman I, Maisey MN (1996) Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron emission tomography scanning: potential for error in interpretation. Semin Nucl Med 26: 308
11. Delbeke D, Vitola JV, Sandler MP, Arildsen RC, et al (1997) Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 38: 1196
12. Dewan NA, Shehan CJ, Reeb SD, Gobar LS, et al (1997) Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan. Chest 112: 416
13. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN (1998) FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 39: 1030
14. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, et al (1998) Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 39: 1197
15. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, et al (1995) Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 110: 130
16. Engel H, Steinert H, Buck A, Berthold T, et al (1996) Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 37: 441
17. Erasmus JJ, McAdams HP, Patz EF, Coleman RE, et al (1998) Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR 170: 1369
18. Findlay M, Young J, Cunningham D, Iveson A, et al (1996) Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil. J Clin Oncol 14: 700
19. Flanagan FL, Dehdashti F, Siegel BA, Trask DD, et al (1997) Staging of esophageal cancer with 18-F-fluorodeoxyglucose positron emission tomography. AJR 168: 417
20. Franke J, Rosenzweig S, Reinartz P, Höer J, et al (2000) Die Wertigkeit der Positronenemissionstomographie (18F-FDG-PET) in der Diagnostik von Rectumrezidivcarcinomen. Chirurg 71: 80
21. Friess H, Langhans J, Ebert M, Beger HG, et al (1995) Diagnosis of pancreatic cancer by 2 [18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 36: 771
22. Frohlich A, Diederichs CG, Staib L, Vogel J, et al (1999) Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 40: 250
23. Goo JM, Im JG, Do KH, Yeo JS, et al (2000) Pulmonary tuberculoma evaluated by means of FDG-PET: findings in 10 cases. Radiology 216: 117
24. Graeber GM, Gupta NC, Murray GF (1999) Positron emission tomography imaging with fluorodeoxyglucose efficacious in evaluating malignant pulmonary disease. J Thorac Cardiovasc Surg 117: 719
25. Gupta NC, Maloof J, Gunel E (1996) Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 37: 943
26. Haberkorn U, Strauss LG, Dimitrakopoulou A, Engenhart R, et al (1991) PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 32: 1485
27. Higashi K, Ueda Y, Seki H, Yuasa K, et al (1998) Fluorine-18-PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 39: 1016
28. Hoh CK, Hawkins RA, Dahlbom M, Glaspy J, et al (1993) Cancer detection with whole body PET with 2-[F-18]fluoro-2-deoxy-D-glucose (FDG). J Comput Assist Tomogr 17: 582
29. Hoh CK, Seltzer MA, Franklin J, deKernion JB, et al (1998) Positron emission tomography in urological oncology. J Urol 159: 347
30. Horton RW, Meldrum BS, Bachelard HS (1973) Enzymatic and cerebral metabolic effects of 2-deoxy-D-glucose. J Neurochem 21: 507
31. Inokuma T, Tamaki N, Torizuka T, Magata Y, et al (1995) Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 195: 345
32. Ito K, Kato T, Ohta T, Tadokoro M, et al (1996) Fluorine-18 fluoro-2-deoxyglucose positron emission tomography in recurrent rectal cancer: relation to tumour size and cellularity. Eur J Nucl Med 23: 1372
33. Keogan MT, Lowe VJ, Baker ME, McDermott VG, et al (1997) Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging. Abdom Imaging 22: 332
34. Keogan MT, Tyler D, Clark L, Branch MS, et al (1998) Diagnosis of pancreatic carcinoma: role of FDG PET. AJR 178: 1565
35. Kole AC, Plukker JT, Nieweg OE, Vaalburg W (1998) Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 78: 521
36. Konsensus - Onko-PET (1997) DGN-Nachrichten. 2. interdisziplinäre Konsensuskonferenz PET bei onkologischen Fragestellungen. Nuklearmedizin 36: 45
37. Lai DT, Fulham M, Stephen MS, Chu KM, et al (1996) The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 131: 703
38. Lapela M, Eigtved A, Jyrkkio S, Grenman R, et al (2000) Experience in qualitative and quantitative FDG-PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur J Cancer 36: 858
39. Lehner B, Schlag P, Strauss L, Dimitrakopoulou A, Herfarth Ch (1990) Die Wertigkeit der Positronen-Emissions-Tomographie für die Diagnostik des Rectumkarzinom-Rezidivs. Zentralbl Chir 115: 813
40. Lorenzen J, Buchert R, Bleckmann C, Munchow N, Bohuslavizki KH (1999) Fokussuche bei Patienten mit Fieber unklarer Genese: Ist die Positronen-Emissions-Tomographie mit F-18-Fluordesoxyglukose hilfreich? Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 171: 49
41. Lowe VJ, Fletcher JW, Gobar L, Lawson M, et al (1998) Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 16: 1075
42. Luketich JD, Schauer PR, Meltzer CC, Landreneau RJ, et al (1997) Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg 64: 765
43. Mathupala SP, Rempel A, Pedersen PL (1997) Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, posttranslational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 29: 339
44. Nakata B, Chung YS, Nishimura S, Nishihara T, et al (1997) 18-F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 79: 695
45. Ogungiyi OA, Flanagan FL, Dehdashti F, Siegel BA, et al (1997) Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 4: 613
46. Patz EF Jr, Lowe VJ, Goodman PC, Herndon J (1995) Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest 108: 1617
47. Phelps ME, Huang SC, Hoffmann EJ, Selin C, et al (1979) Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18) 2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 6: 371
48. Rankin SC, Taylor H, Cook CJR, Mason R (1998) Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clin Radiol 53: 659
49. Reske SN, Grillenberger KG, Glatting G, Port M, et al (1997) Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 38: 1344
50. Reske SN, Guhlmann A, Schirrmeister H (1998) Positronen-Emissions-Tomographie in der Diagnostik abdomineller Tumore. Schweiz Med Wochenschr 128: 96
51. Sasaki M, Ichiya Y, Kuwabara Y, Akashi Y, et al (1996) The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med 23: 741
52. Sazon DA, Santiago SM, Soo Hoo GW, Khonsary A, et al (1996) Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 153: 417
53. Schek N, Hall BL, Finn OJ (1988) Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human pancreas. Cancer Res 48: 6354
54. Schiepers C, Penninckx F, De-Vadder N, Meckx E, et al (1995) Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 21: 517
55. Schober O, Lottes G (1994) Positronen-Emissionstomographie und Strahlenexposition. Nuklearmedizin 33: 174
56. Schulte M, Brecht-Kraus D, Heymer B, Guhlmann A, et al (1999) Fluorodeoxyglucose positron emission tomography of soft tissue tumors: is a non-invasive determination of biological activity possible. Eur J Nucl Med 26: 599
57. Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, et al (2000) Grading of tumors and tumorlike lesions of bone: evaluation by FDG-PET. J Nucl Med 41: 1695
58. Shinohara M, Tomita M, Ohira S, Nishimura A (1999) Evaluation of 18F-FDG positron emission tomography (PET) in the detection of unknown primary tumors. Hokkaido Igaku Zasshi 74: 249
59. Steinert HC, Hauser M, Allemann F, Engel H, et al (1997) Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 202: 441
60. Torizuka T, Tamaki N, Inokuma T, Magata Y, et al (1995) In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36: 1811
61. Valk PE, Pounds TR, Hopkins DM, Haseman MK, et al (1995) Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 60: 1573
62. Warburg O (1931) The metabolism of tumors. Smith, New York, p 129
63. Woesler B, Kuwert T, Morgenroth C, Matheja P, et al (1997) Non-invasive grading of primary brain tumors: result of a comparative study between SPET with I-123 alpha-methyl tyrosine and PET with F-18-deoxyglucose. Eur J Nucl Med 24: 428
64. Yasuda S, Takahashi W, Takagi S, Ide M, Shohtsu A (1998) Primary colorectal cancers detected with PET. Jpn J Clin Oncol 28: 638
65. Zimny M, Bares R, Faß J, Adam G, et al (1997) Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 24: 678